Resultados da busca - Rachel Nering
- Mostrando 1 - 3 resultados de 3
-
1
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations por Sabrina Arena, Giulia Siravegna, Benedetta Mussolin, Jeffrey D. Kearns, Beni B. Wolf, Sandra Misale, Luca Lazzari, Andrea Bertotti, Livio Trusolino, Alex A. Adjei, Clara Montagut, Federica Di Nicolantonio, Rachel Nering, Alberto Bardelli
Publicado em 2016Artigo -
2
Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer por Joyce F. Liu, Isabelle Ray‐Coquard, Frédèric Selle, Andrés Poveda, David Cibula, Hal W. Hirte, Felix Hilpert, Francesco Raspagliesi, Laurence Gladieff, Philipp Harter, Salvatore Siena, Josep M. del Campo, Isabelle Tabah-Fisch, Joseph Pearlberg, Victor Moyo, Kaveh Riahi, Rachel Nering, William Kubasek, Bambang S. Adiwijaya, Akos Czibere, R. Wendel Naumann, Robert L. Coleman, Ignace Vergote, Gavin MacBeath, Éric Pujade-Lauraine
Publicado em 2016Artigo -
3
Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121) por Birgit Schoeberl, Art Kudla, Kristina Masson, Ashish Kalra, Michael Curley, Gregory J. Finn, Emily Pace, Brian D. Harms, Jaeyeon Kim, Kearns Jeff, Aaron Fulgham, Olga Burenkova, Viara Grantcharova, Defne Yarar, Violette Paragas, Jonathan B. Fitzgerald, Marisa J. Wainszelbaum, Kip A. West, Sara Mathews, Rachel Nering, Bambang S. Adiwijaya, Gabriela Garcia, Bill Kubasek, Victor Moyo, Akos Czibere, Ulrik B. Nielsen, Gavin MacBeath
Publicado em 2017Revisão
Ferramentas de busca:
Assuntos relacionados
Cancer
Internal medicine
Medicine
Biology
Cancer research
Epidermal growth factor receptor
Oncology
Acquired resistance
Carcinogenesis
Cell biology
Cetuximab
Chemotherapy
Colorectal cancer
Confidence interval
Drug resistance
ERBB3
Environmental health
ErbB
Extracellular
Gastroenterology
Gene
Genetics
Hazard ratio
KRAS
Mutation
Neuregulin
Ovarian cancer
Paclitaxel
Panitumumab
Population